- /
- Supported exchanges
- / US
- / ARCT.NASDAQ
Arcturus Therapeutics Holdings Inc (ARCT NASDAQ) stock market data APIs
Arcturus Therapeutics Holdings Inc Financial Data Overview
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Arcturus Therapeutics Holdings Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Arcturus Therapeutics Holdings Inc data using free add-ons & libraries
Get Arcturus Therapeutics Holdings Inc Fundamental Data
Arcturus Therapeutics Holdings Inc Fundamental data includes:
- Net Revenue: 122 M
- EBITDA: -69 262 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 5.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arcturus Therapeutics Holdings Inc News
New
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Fate Therapeutics (FATE) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outloo...
High Growth Tech Stocks In US With Promising Potential
The U.S. market has recently experienced mostly positive momentum, with major indices like the Nasdaq and S&P 500 showing gains following strong earnings reports from big tech companies such as Amazon...
2 Stocks to Buy Under $10 That Wall Street Loves
Penny stocks often get a bad reputation for being risky and volatile, but not all low-priced stocks are created equal. Wall Street analysts occasionally identify hidden gems in this space, stocks that...
Arcturus cut to Neutral at Citi on data for mRNA candidate
[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Arcturus Therapeutics (NASDAQ:ARCT [https://seekingalpha.com/symbol/ARCT]) traded lower on Friday after Citi downgraded the San Di...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.